academic article

• Generic oncology drugs: are they all safe?.  The Lancet. Oncology.  17:e493-e501. 2016
• Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system..  Expert opinion on drug safety.  :-. 2016
• Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system..  Expert opinion on drug safety.  :1-8. 2015
• Regulatory and clinical considerations for biosimilar oncology drugs..  The Lancet. Oncology.  15:e594-e605. 2014
• A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR)..  Seminars in thrombosis and hemostasis.  38:783-796. 2012
• Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR)..  Seminars in thrombosis and hemostasis.  38:845-853. 2012